Effects of Micronized Fenofibrate on Fasting and Postprandial Lipoproteins, Inflammatory Mediators and Thrombosis

Inclusion Criteria: 1. males and postmenopausal females 18 years of age with fasting triglycerides greater than or equal to 1.7 mmol/L and \<6.9 mmol/L 2. two or more of the following Adult Treatment Panel III (1) criteria of the metabolic syndrome: abdominal obesity (waist circumference \>89 cm in females and \>102 cm in males); low high-density lipoprotein cholesterol (HDL-C) (\<1.3 mmol/L in women and \<1.0 mmol/L in men); hypertension (systolic blood pressure \>130 or diastolic blood pressure \>85 mm Hg) or current drug therapy for hypertension; and impaired fasting glucose (between 6.1 mmol/L and 7.0 mmol/L). Exclusion Criteria: 1. included types 1 or 2 diabetes 2. Body mass index \>40 kg/m2 3. Use of lipid-lowering therapies 4. Oral hypoglycemic therapies 5. Insulin 6. Aspirin \>81 mg daily 7. Regular use of non-steroidal anti-inflammatory agents or cyclooxygenase-2 inhibitors, corticosteroids (oral and inhaled), anti-oxidants (including multivitamins), herbal or fiber supplements recent changes in type or formulation of hormone replacement therapy (in the last 6 months) 8. Alcohol intake \>3 drinks per day 9. Untreated hypothyroidism or recent change (within 2 months) of thyroid replacement therapy 10. Cigarette smoking (current or within the last 6 months)